Colcrys (colchicine)

August 3, 2024

Taking Colchicine to Treat Gout

Indications, Dosages, and Common Side Effects

By Carol Eustice
Updated on August 03, 2024
Medically reviewed by Stella Bard, MD

Understanding Gout and Colchicine's Role

Gout is a complex form of arthritis characterized by sudden, severe attacks of pain, swelling, redness, and tenderness in the joints, often affecting the big toe. These painful flares occur when urate crystals accumulate in the joint, triggering an intense inflammatory response. While other treatments focus on lowering uric acid levels, colchicine plays a crucial role in directly addressing the inflammatory process that causes the acute pain and discomfort associated with gout attacks.

The use of Colchicum autumnale alkaloids for treating gout has a remarkably long history, with documented medicinal value dating back to the first century A.D., and its specific application for gout treatment recorded as early as 1810. This extensive historical lineage speaks to its consistent effectiveness and established place in medical therapy for inflammatory conditions. While gout remains its most prominent indication, colchicine's anti-inflammatory mechanisms lend it utility in managing several other inflammatory disorders, highlighting its versatility.

Foot pain from gout.
Jan-Otto/E+/Getty Images

Indications for Using Colchicine

Beyond its primary role in treating gout, colchicine is also indicated for the management of several other conditions due to its unique anti-inflammatory actions. These diverse applications demonstrate its broad therapeutic potential, although its use in these contexts is often for managing inflammatory symptoms rather than addressing the underlying cause. Patients often find relief from specific manifestations of these conditions through colchicine therapy.

Some of the conditions for which colchicine may be prescribed include:

Amyloidosis^2: This rare disease occurs when an abnormal protein called amyloid builds up in organs, leading to dysfunction. Colchicine, particularly in specific types like Familial Amyloidosis, can help reduce the inflammation and slow the progression of amyloid deposition, thereby mitigating organ damage and improving patient quality of life by controlling the inflammatory processes linked to the disease.
Behcet's disease^3: A rare, chronic inflammatory disorder affecting various parts of the body, including blood vessels, skin, joints, and nervous system. Colchicine is used to manage the inflammatory symptoms, particularly mucocutaneous lesions (mouth sores and genital ulcers) and joint pain, helping to reduce the frequency and severity of flares and improve overall disease control for affected individuals.
Dermatitis herpetiformis^4: This is a chronic, intensely itchy blistering skin condition associated with celiac disease. While a gluten-free diet is the primary treatment, colchicine can sometimes be used as an adjunctive therapy to help alleviate the severe itching and skin lesions by modulating the immune response, offering additional relief when standard treatments may not be fully effective on their own.
Familial Mediterranean fever^5: An inherited inflammatory disorder characterized by recurrent episodes of fever, abdominal pain, joint pain, and chest pain. Colchicine is the cornerstone of treatment for this condition, effectively preventing or significantly reducing the frequency and severity of inflammatory attacks, thereby preventing long-term complications like amyloidosis and improving patient well-being.
Paget's disease^6: A chronic bone disorder characterized by abnormal bone remodeling, leading to weakened and misshapen bones. While bisphosphonates are the main treatment, colchicine has been explored for its anti-inflammatory effects in managing associated pain, though its role is typically secondary. Its use in this context aims to alleviate inflammatory symptoms rather than addressing the bone pathology directly.
Pericarditis^7: Inflammation of the pericardium, the sac-like membrane surrounding the heart. Colchicine is increasingly recognized as an effective and often first-line treatment for acute and recurrent pericarditis due to its potent anti-inflammatory effects, helping to reduce pain, prevent recurrences, and shorten the duration of symptoms. Its mechanism helps stabilize the inflammatory response around the heart.
Pseudogout^8: Similar to gout, pseudogout is caused by the deposition of calcium pyrophosphate crystals in the joints, leading to acute inflammatory arthritis. Colchicine can be used to treat acute attacks and as prophylactic therapy to prevent recurrences, acting through similar anti-inflammatory pathways as in gout to mitigate joint pain and swelling.

Mechanism of Action

While colchicine possesses potent anti-inflammatory properties, it's crucial to understand that its efficacy is highly specific to certain inflammatory pathways and generally limited in treating pain from causes other than gout or conditions with similar inflammatory mechanisms. It is not classified as an analgesic (pain-relieving medication) in the traditional sense, nor does it directly impact the elevated uric acid levels that are characteristic of gout^9. Its therapeutic action in gout is primarily achieved by disrupting the inflammatory cascade triggered by uric acid crystals.

The unique mechanism of action of colchicine involves its interaction with a specific type of white blood cell known as a neutrophil. Neutrophils are a vital component of the immune system and are among the first cells to respond to inflammation or infection. In the context of gout, when uric acid crystals accumulate in a joint, they trigger an acute inflammatory response, attracting these neutrophils to the affected area.

Colchicine works by binding to a protein called tubulin, which is essential for the formation of microtubules within cells. By interfering with microtubule assembly, colchicine disrupts several key cellular functions, most notably the ability of neutrophils to migrate to sites of inflammation and their capacity to phagocytose (engulf) uric acid crystals. This targeted action prevents neutrophils from effectively responding to the crystal deposition, thereby tempering the robust inflammatory response and significantly alleviating much of the associated pain and swelling.

Furthermore, colchicine has a suppressive effect that helps to decrease the frequency and intensity of acute gout attacks. By reducing the inflammatory signaling and the influx of neutrophils, it effectively dampens the body's overzealous immune reaction to uric acid crystals. This prophylactic benefit is invaluable for patients experiencing recurrent flares, leading to considerable relief from the chronic pain and discomfort often associated with persistent gout.

Dosages

Colchicine is typically initiated in gout patients who experience two or more attacks annually, signaling a need for more proactive management. The standard starting dose for prophylaxis, often alongside uric acid-lowering therapy (ULT) like Uloric (febuxostat) or allopurinol, is two 0.6 mg colchicine tablets daily. This regimen continues until serum uric acid levels are consistently maintained below a target of 6.0 mg/dL, a crucial threshold for preventing crystal formation and future flares.

For managing acute gout flares, the dosage of colchicine may be temporarily increased to three tablets daily for a few days to rapidly bring the inflammation under control. However, it is imperative to monitor for gastrointestinal discomfort, such as nausea, vomiting, or diarrhea. Should such side effects arise, the daily dose should be promptly decreased, sometimes to as little as one tablet daily, to maintain patient comfort and adherence to the treatment plan. Discontinuation of the drug is advised if severe gastrointestinal symptoms or diarrhea occur, as these can indicate toxicity.

Gout Prevention

Colchicine is also strongly recommended for regular use between gout attacks as a prophylactic (preventive) therapy. This sustained approach helps to prevent the recurrence of painful flares, especially during the initial phase of uric acid-lowering therapy when the risk of attacks can paradoxically increase as uric acid levels shift. Consistent prophylactic dosing is key to maintaining long-term disease control and improving the patient's quality of life.

For individuals who experience less than one gout attack per year, a typical preventive dose is 0.5 or 0.6 mg administered three or four days per week. However, for those with more frequent attacks, exceeding one flare annually, the usual recommended dose is 0.5 or 0.6 mg daily. In more severe or refractory cases, a physician might prescribe two or even three 0.5 mg or 0.6 mg tablets daily, carefully balancing efficacy with potential side effects to achieve optimal disease control^9.

While colchicine is primarily reserved for use in adults experiencing acute gout flares, its prophylactic benefits extend to adolescents aged 16 and over, offering a crucial preventive measure in younger populations prone to gout. Notably, its only approved use in children under 16 is for the specific treatment of familial Mediterranean fever (FMF), highlighting its targeted efficacy in managing this particular inherited inflammatory condition due to its potent anti-inflammatory properties.

Side Effects

Adverse reactions are a potential concern with colchicine use, and patients must be fully aware of these possibilities. One of the most serious, albeit rare, adverse reactions is bone marrow depression, which can manifest as aplastic anemia (a severe decrease in all blood cell types), agranulocytosis (a critical reduction in white blood cells, increasing infection risk), or thrombocytopenia (low platelet count, increasing bleeding risk). These serious hematological complications may occur in individuals receiving long-term therapy, necessitating regular blood monitoring.

Other possible adverse reactions include:

Peripheral neuritis: This refers to nerve damage outside of the brain and spinal cord, which can lead to symptoms such as weakness, numbness, and pain, typically in the hands and feet. This rare side effect underscores the need for careful neurological monitoring during treatment.
Purpura: Characterized by purple-colored spots on the skin caused by small blood vessel leakage. This can be a sign of underlying issues with blood clotting or vessel integrity, requiring medical evaluation if it appears.
Myopathy^11: Muscle weakness or pain, sometimes accompanied by elevated muscle enzymes. This side effect can be particularly concerning and warrants discontinuation if suspected, especially in patients with pre-existing muscle conditions or those on other medications that can cause myopathy.
Hair loss: While generally reversible upon discontinuation of the medication, hair thinning or loss can be a distressing side effect for some patients. It's important for patients to be aware of this possibility, though it is usually not severe enough to warrant stopping treatment.
Reversible azoospermia^12: This refers to the complete absence of sperm in semen, potentially impacting male fertility. While typically reversible after the medication is stopped, it is an important consideration for male patients of reproductive age who are planning to conceive.

Vomiting, diarrhea, and nausea are among the most common gastrointestinal side effects associated with colchicine therapy, particularly when higher or maximum doses are prescribed. These symptoms are often dose-dependent and can significantly impact a patient's adherence to treatment. To minimize these bothersome side effects and improve tolerability, colchicine may be taken with food, which can help buffer its effects on the digestive system^10. Patients should promptly report any persistent or severe gastrointestinal discomfort to their healthcare provider.

Considerations and Contraindications for Taking Colchicine

When considering colchicine therapy, a thorough evaluation of individual patient circumstances and potential risks is paramount. Pregnant women, in particular, must weigh the potential benefits of using colchicine against the inherent risks to the developing fetus. Colchicine has the known ability to arrest cell division, a fundamental biological process crucial for fetal development. Therefore, it should only be administered during pregnancy if the anticipated therapeutic benefit significantly outweighs the potential risk of harm to the fetus. Similar caution should be exercised when colchicine is administered to a woman who is nursing, as the drug may pass into breast milk^13.

Patients should download a Gout Doctor Discussion Guide to help them ask the right questions during their appointments.

Download PDF

Furthermore, colchicine is strictly contraindicated for individuals with a known hypersensitivity or allergic reaction to the drug, as this could lead to severe adverse responses. It should also not be used by anyone diagnosed with serious gastrointestinal, renal (kidney), hepatic (liver), or cardiac (heart) disorders^10. This is because these conditions can impair the body's ability to process and eliminate the drug, increasing the risk of toxicity and exacerbating existing health issues.

Patients with pre-existing blood disorders are also advised against using colchicine due to the potential for worsening bone marrow suppression and associated complications. Given these significant considerations and contraindications, it is imperative for patients to disclose their complete medical history, including all current medications and pre-existing conditions, to their healthcare provider. This comprehensive approach ensures that colchicine therapy is both safe and effective for the individual.

13 Sources

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Colchicine.
Unverdi S, Inal S, Ceri M, et al. Is colchicine therapy effective in all patients with secondary amyloidosis?. Ren Fail. 2013;35(8):1071-4. doi:10.3109/0886022X.2013.811345
Nair JR, Moots RJ. Behcet's disease. Clin Med (Lond). 2017;17(1):71-77. doi:10.7861/clinmedicine.17-1-71
Silvers DN, Juhlin EA, Berczeller PH, Mcsorley J. Treatment of dermatitis herpetiformis with colchicine. Arch Dermatol.
Sönmez HE, Batu ED, Özen S. Familial Mediterranean fever: current perspectives. J Inflamm Res. 2016;9:13-20. doi:10.2147/JIR.S91352
Theodors A, Askari AD, Wieland RG. Colchicine in the treatment of Paget disease of bone: a new therapeutic approach. Clin Ther.
Alabed S, Cabello JB, Irving GJ, Qintar M, Burls A. Colchicine for pericarditis. Cochrane Database Syst Rev. 2014;(8):CD010652. doi:10.1002/14651858.CD010652.pub2.
Macmullan P, Mccarthy G. Treatment and management of pseudogout: insights for the clinician. Ther Adv Musculoskelet Dis. 2012;4(2):121-31. doi:10.1177/1759720X11432559
Engel B, Just J, Bleckwenn M, Weckbecker K. Treatment Options for Gout. Dtsch Arztebl Int. 2017;114(13):215-222. doi:10.3238/arztebl.2017.0215
Sadiq NM, Robinson KJ, Terrell JM. Colchicine. In: StatPearls. Treasure Island (FL): StatPearls Publishing.
Altiparmak MR, Pamuk ON, Pamuk GE, Hamuryudan V, Ataman R, Serdengecti K. Colchicine neuromyopathy: a report of six cases. Clin Exp Rheumatol.
Ding J, Shang X, Zhang Z, et al. FDA-approved medications that impair human spermatogenesis. Oncotarget. 2017;8(6):10714-10725. doi:10.18632/oncotarget.12956
Indraratna PL, Virk S, Gurram D, Day RO. Use of colchicine in pregnancy: a systematic review and meta-analysis. Rheumatology (Oxford). 2018;57(2):382-387. doi:10.1093/rheumatology/kex353

Additional Reading

Colchicine. RxList. The Internet Drug Index.
Kelley's Textbook of Rheumatology. Elsevier. Ninth edition. Chapter 95: Clinical Features and Treatment of Gout - Colchicine.
Colcrys.
Colchicine. MedlinePlus.

Sign up for our Health Tip of the Day newsletter, and receive daily tips that will help you live your healthiest life.
Email Address
Sign Up
You're in!
Thank you, , for signing up.
There was an error. Please try again.

Taking Colchicine to Treat Gout

Indications, Dosages, and Common Side Effects

By Carol Eustice
Updated on August 03, 2024
Medically reviewed by Stella Bard, MD

Colchicine is a potent prescription medication widely utilized for its anti-inflammatory properties, primarily in the management of gouty arthritis. Available under the brand name Colcrys and in generic formulations, this ancient remedy traces its origins to the dried seeds of Colchicum autumnale, commonly known as the autumn crocus or meadow saffron^1. Its historical use underscores its enduring efficacy, yet its specific mechanism and appropriate application require careful understanding for optimal patient outcomes. This article will delve into the indications for colchicine, its precise mechanism of action, recommended dosages for both acute and prophylactic use, potential side effects, and important considerations or contraindications to ensure safe and effective treatment.

Understanding Gout and Colchicine's Role

Gout is a complex and often debilitating form of inflammatory arthritis characterized by sudden, severe attacks of pain, swelling, redness, and tenderness in the joints, most commonly affecting the big toe. These painful flares occur when urate crystals, formed from an excess of uric acid in the blood, accumulate within a joint, triggering an intense and localized inflammatory response. While other treatments for gout focus on lowering systemic uric acid levels to prevent crystal formation, colchicine plays a crucial and distinct role by directly addressing the acute inflammatory process that drives the debilitating pain and discomfort during a flare.

The use of Colchicum autumnale alkaloids for treating gout has a remarkably long and well-documented history. Its medicinal value was first reported in the first century A.D., and its specific application for gout treatment was recorded as early as 1810. This extensive historical lineage speaks volumes about its consistent effectiveness and established place in medical therapy for acute inflammatory conditions. This enduring legacy also highlights the deep understanding of its therapeutic properties even before modern pharmacological insights, making it a cornerstone in gout management for centuries.

While gout remains its most prominent indication, colchicine's unique anti-inflammatory mechanisms lend it utility in managing several other inflammatory disorders. This versatility stems from its ability to modulate specific immune responses rather than acting as a general painkiller or uric acid reducer. Its broad therapeutic potential allows it to address the inflammatory components of various conditions, offering targeted symptomatic relief. However, each application is carefully considered based on its specific inflammatory profile and clinical evidence.

Foot pain from gout.
Jan-Otto/E+/Getty Images

Indications for Using Colchicine

Beyond its primary role in treating acute gout flares and preventing recurrent attacks, colchicine is also indicated for the management of several other conditions due to its unique anti-inflammatory actions. These diverse applications demonstrate its broad therapeutic potential, although its use in these contexts is typically for managing inflammatory symptoms rather than addressing the underlying cause of the disease. Patients often find significant relief from specific manifestations of these complex inflammatory conditions through targeted colchicine therapy.

Some of the conditions for which colchicine may be prescribed include:

Amyloidosis^2: This is a rare group of diseases characterized by the abnormal buildup of amyloid proteins in various organs and tissues, leading to their dysfunction. In certain types, particularly familial amyloidosis, colchicine can help by reducing the inflammation associated with the disease and, in some cases, slowing the rate of amyloid deposition. This can be crucial in preserving organ function and improving prognosis by mitigating the inflammatory processes that contribute to the disease's progression.
Behcet's disease^3: A chronic, multisystem inflammatory disorder that can affect various parts of the body, including blood vessels, skin, joints, eyes, and the nervous system. Colchicine is frequently used to manage the inflammatory symptoms, particularly recurrent mucocutaneous lesions (painful mouth and genital ulcers) and joint pain. Its anti-inflammatory action helps to reduce the frequency and severity of flares, contributing to better disease control and enhancing the patient's quality of life by mitigating the chronic inflammatory burden.
Dermatitis herpetiformis^4: This is a chronic, intensely itchy blistering skin condition that is closely associated with celiac disease. While a strict gluten-free diet is the primary and most effective treatment for dermatitis herpetiformis, colchicine can sometimes be used as an adjunctive therapy. It helps to alleviate the severe itching and characteristic skin lesions by modulating the immune response, offering additional symptomatic relief when dietary changes alone may not be fully effective or during the initial phases of dietary adjustment.
Familial Mediterranean fever (FMF)^5: An inherited inflammatory disorder characterized by recurrent, self-limiting episodes of fever accompanied by inflammation of the peritoneum (abdominal pain), pleura (chest pain), or synovium (joint pain). Colchicine is the cornerstone of treatment for FMF; its consistent use effectively prevents or significantly reduces the frequency and severity of these inflammatory attacks. Importantly, long-term colchicine therapy in FMF is critical for preventing serious complications like amyloidosis, which can lead to organ damage.
Paget's disease^6: This is a chronic bone disorder characterized by abnormal bone remodeling, leading to weakened, enlarged, and often misshapen bones. While bisphosphonates are the primary medications used to manage the underlying bone pathology, colchicine has been explored for its anti-inflammatory effects in managing associated pain, particularly when inflammation is a significant component. However, its role is typically secondary and focused on symptomatic relief rather than directly addressing the bone abnormalities.
Pericarditis^7: This condition involves inflammation of the pericardium, the thin, sac-like membrane that surrounds the heart. Colchicine has gained significant recognition as an effective and often first-line treatment for both acute and recurrent pericarditis. Its potent anti-inflammatory effects help to reduce chest pain, prevent the recurrence of inflammatory episodes, and shorten the overall duration of symptoms. Colchicine's mechanism helps to stabilize the inflammatory response affecting the delicate tissues surrounding the heart.
Pseudogout^8: Also known as calcium pyrophosphate deposition disease (CPPD), pseudogout shares similarities with gout but is caused by the deposition of calcium pyrophosphate crystals in the joints, rather than uric acid. This leads to acute inflammatory arthritis characterized by pain, swelling, and redness. Colchicine can be effectively used to treat acute pseudogout attacks and also as a prophylactic therapy to prevent recurrences, acting through similar anti-inflammatory pathways as it does in gout to mitigate joint pain and swelling.

Mechanism of Action

While colchicine possesses potent anti-inflammatory properties, it is crucial to understand that its therapeutic efficacy is highly specific to certain inflammatory pathways and generally limited in treating pain from causes other than gout or conditions that share similar inflammatory mechanisms. It is not classified as an analgesic (a general pain-relieving medication) in the traditional sense, nor does it directly impact the elevated uric acid levels that are characteristic of gout^9. Its primary therapeutic action in gout is achieved by selectively disrupting the inflammatory cascade triggered by the deposition of uric acid crystals within joint tissues.

The unique mechanism of action of colchicine involves its critical interaction with a specific type of white blood cell known as a neutrophil. Neutrophils are highly abundant immune cells and are typically among the very first responders to sites of inflammation or infection in the body. In the context of a gout flare, when uric acid crystals are released into the joint, they are recognized as foreign invaders, triggering an immediate and intense inflammatory response that rapidly recruits large numbers of these neutrophils to the affected area.

Colchicine exerts its effect by binding to a protein called tubulin, which is a fundamental building block for the formation of microtubules within cells. Microtubules are essential cellular structures involved in various vital functions, including cell shape maintenance, intracellular transport, and, critically, cell migration. By interfering with microtubule assembly, colchicine effectively disrupts several key cellular functions of neutrophils, most notably their ability to migrate efficiently to sites of inflammation and their capacity to engulf (phagocytose) uric acid crystals. This targeted action prevents neutrophils from actively participating in the inflammatory cascade.

This disruption of neutrophil function profoundly impacts the inflammatory response in gout. By hindering the migration and activity of these key inflammatory cells, colchicine effectively dampens the release of pro-inflammatory mediators and the subsequent tissue damage that characterizes an acute gout attack. This selective anti-inflammatory effect directly translates to a significant reduction in the severe pain, swelling, and tenderness experienced by patients during a gout flare, providing targeted relief without directly affecting uric acid levels.

Furthermore, beyond its acute flare management, colchicine also has a suppressive effect that helps to decrease the frequency and intensity of recurrent gout attacks. By consistently reducing the inflammatory signaling and the uncontrolled influx of neutrophils, it effectively dampens the body's overzealous immune reaction to residual or newly forming uric acid crystals. This powerful prophylactic benefit is invaluable for patients experiencing recurrent flares, leading to considerable long-term relief from the chronic pain and discomfort often associated with persistent gout, thereby improving overall disease management and patient well-being.

Dosages

Colchicine therapy is typically initiated in gout patients who experience two or more acute attacks per year, indicating a need for consistent management beyond episodic treatment. The standard starting dose for prophylactic purposes, often prescribed concurrently with uric acid-lowering therapy (ULT) such as febuxostat (Uloric) or allopurinol, is two 0.6 mg colchicine tablets administered daily. This regimen is continued while the ULT is titrated, and until serum uric acid levels are consistently maintained below a target of 6.0 mg/dL, a crucial threshold for preventing future crystal formation and subsequent flares.

For the prompt management of acute gout flares, the dosage of colchicine may be temporarily increased to three 0.6 mg tablets per day for a few days to rapidly bring the inflammation under control. It is imperative to closely monitor for gastrointestinal discomfort, such as nausea, vomiting, or diarrhea, during this higher-dose regimen. Should these side effects arise, the daily dose must be promptly decreased, sometimes to as little as one tablet daily, to ensure patient comfort and adherence to the treatment plan. Discontinuation of the drug is advised if severe gastrointestinal symptoms or persistent diarrhea occur, as these can be indicators of drug toxicity.

Gout Prevention

Colchicine is also strongly recommended for regular use between gout attacks as a prophylactic (preventive) therapy. This sustained approach is crucial not only for preventing the recurrence of painful flares but also, importantly, during the initial phase of uric acid-lowering therapy. During this period, uric acid levels can fluctuate, sometimes paradoxically increasing the risk of acute attacks as existing crystals dissolve, making consistent prophylactic colchicine use a vital strategy to bridge this vulnerable phase.

For individuals who experience less than one gout attack per year, a typical preventive dose of colchicine is 0.5 or 0.6 mg administered three or four days per week. However, for those with more frequent attacks, specifically exceeding one flare annually, the usual recommended dose is 0.5 or 0.6 mg daily. In more severe or refractory cases, a physician might prescribe two or even three 0.5 mg or 0.6 mg tablets daily, carefully balancing efficacy with the potential for adverse effects to achieve optimal disease control and minimize the impact of recurrent flares^9.

While colchicine is primarily reserved for use in adults experiencing acute gout flares, its prophylactic benefits extend to adolescents aged 16 and over, offering a crucial preventive measure in younger populations prone to gout. Notably, its only approved use in children under the age of 16 is for the specific treatment of familial Mediterranean fever (FMF), highlighting its targeted efficacy in managing this particular inherited inflammatory condition. This differentiation underscores the importance of precise diagnosis and age-appropriate prescribing.

Side Effects

Adverse reactions are a potential concern with colchicine use, and patients must be fully aware of these possibilities to facilitate timely reporting and management. One of the most serious, albeit rare, adverse reactions that can occur with long-term colchicine therapy is bone marrow depression. This condition can manifest in various forms, including aplastic anemia (a severe deficiency of all types of blood cells), agranulocytosis (a critical reduction in specific white blood cells, significantly increasing the risk of infection), or thrombocytopenia (a low platelet count, which impairs blood clotting and increases bleeding risk)^10. Regular monitoring of blood counts is essential for patients on long-term therapy to detect and manage these serious complications.

Other possible adverse reactions that patients should be aware of include:

Peripheral neuritis: This refers to nerve damage outside of the brain and spinal cord, which can manifest as symptoms such as weakness, numbness, tingling, or pain, typically in the hands and feet. While rare, its occurrence underscores the need for careful neurological assessment during prolonged treatment, especially if new sensory or motor deficits arise.
Purpura: Characterized by purple-colored spots on the skin caused by small blood vessel leakage. While not always serious, the appearance of purpura should prompt medical evaluation to rule out underlying issues with blood clotting or vessel integrity that may be related to drug effects.
Myopathy^11: This condition involves muscle weakness or pain, sometimes accompanied by elevated muscle enzymes (e.g., creatine kinase) in blood tests. Myopathy can be particularly concerning and warrants prompt discontinuation of the drug if suspected, especially in patients with pre-existing muscle conditions or those concomitantly using other medications known to cause myopathy, such as statins.
Hair loss: While generally reversible upon discontinuation of the medication, hair thinning or diffuse hair loss can be a distressing side effect for some patients. It's important for patients to be aware of this possibility, though it is usually not severe enough to warrant stopping treatment unless deeply impactful to the individual.
Reversible azoospermia^12: This refers to the complete absence of sperm in semen, which can potentially impact male fertility. While typically reversible after the medication is stopped, it is an important consideration for male patients of reproductive age who are planning to conceive and should be discussed with their healthcare provider prior to initiation of therapy.

Vomiting, diarrhea, and nausea are among the most common gastrointestinal side effects associated with colchicine therapy, particularly when higher or maximum doses are prescribed. These symptoms are frequently dose-dependent and can significantly impact a patient's adherence to treatment, potentially leading to discontinuation if not managed effectively. To minimize these bothersome side effects and improve tolerability, colchicine may be taken with food, which can help buffer its effects on the digestive system and reduce gastric irritation^10. Patients should promptly report any persistent or severe gastrointestinal discomfort to their healthcare provider for dosage adjustment or alternative strategies.

Considerations and Contraindications for Taking Colchicine

When considering colchicine therapy, a thorough evaluation of individual patient circumstances, pre-existing conditions, and potential drug interactions is paramount to ensure patient safety and optimize treatment outcomes. Pregnant women, in particular, must carefully weigh the potential benefits of using colchicine against the inherent and significant risks to the developing fetus. Colchicine has the known ability to arrest cell division, a fundamental biological process crucial for the rapid growth and differentiation of fetal cells. Therefore, it should only be administered during pregnancy if the anticipated therapeutic benefit is absolutely indispensable and significantly outweighs the potential risk of harm to the fetus^13.

Similar caution should be exercised when colchicine is administered to a woman who is nursing, as the drug may pass into breast milk, potentially affecting the infant. Healthcare providers will evaluate the need for the medication in the mother versus the potential exposure to the infant, sometimes recommending temporary cessation of breastfeeding or an alternative medication. The decision to use colchicine in these sensitive populations is complex and requires individualized medical judgment, often necessitating consultation with specialists to minimize risks to both mother and child.

Patients should download a Gout Doctor Discussion Guide to help them ask the right questions during their appointments.

Download PDF

Furthermore, colchicine is strictly contraindicated for individuals with a known hypersensitivity or allergic reaction to the drug, as this could lead to severe and potentially life-threatening adverse responses. It should also not be used by anyone diagnosed with serious gastrointestinal, renal (kidney), hepatic (liver), or cardiac (heart) disorders^10. This is because these vital organs are crucial for the body's metabolism and elimination of colchicine. Impaired function in any of these systems can lead to an accumulation of the drug in the body, significantly increasing the risk of toxicity, and potentially exacerbating existing health issues, making the drug unsafe for use.

Individuals with pre-existing blood disorders are also strongly advised against using colchicine due to the potential for worsening bone marrow suppression and associated hematological complications, such as severe reductions in blood cell counts. Given these significant considerations and contraindications, it is absolutely imperative for patients to disclose their complete and accurate medical history, including all current medications (prescription, over-the-counter, and supplements) and any pre-existing health conditions, to their healthcare provider. This comprehensive approach ensures that colchicine therapy is not only effective for managing gout or other inflammatory conditions but also safe and appropriately tailored to the individual's specific health profile.

13 Sources

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Colchicine.
Unverdi S, Inal S, Ceri M, et al. Is colchicine therapy effective in all patients with secondary amyloidosis?. Ren Fail. 2013;35(8):1071-4. doi:10.3109/0886022X.2013.811345
Nair JR, Moots RJ. Behcet's disease. Clin Med (Lond). 2017;17(1):71-77. doi:10.7861/clinmedicine.17-1-71
Silvers DN, Juhlin EA, Berczeller PH, Mcsorley J. Treatment of dermatitis herpetiformis with colchicine. Arch Dermatol.
Sönmez HE, Batu ED, Özen S. Familial Mediterranean fever: current perspectives. J Inflamm Res. 2016;9:13-20. doi:10.2147/JIR.S91352
Theodors A, Askari AD, Wieland RG. Colchicine in the treatment of Paget disease of bone: a new therapeutic approach. Clin Ther.
Alabed S, Cabello JB, Irving GJ, Qintar M, Burls A. Colchicine for pericarditis. Cochrane Database Syst Rev. 2014;(8):CD010652. doi:10.1002/14651858.CD010652.pub2.
Macmullan P, Mccarthy G. Treatment and management of pseudogout: insights for the clinician. Ther Adv Musculoskelet Dis. 2012;4(2):121-31. doi:10.1177/1759720X11432559
Engel B, Just J, Bleckwenn M, Weckbecker K. Treatment Options for Gout. Dtsch Arztebl Int. 2017;114(13):215-222. doi:10.3238/arztebl.2017.0215
Sadiq NM, Robinson KJ, Terrell JM. Colchicine. In: StatPearls. Treasure Island (FL): StatPearls Publishing.
Altiparmak MR, Pamuk ON, Pamuk GE, Hamuryudan V, Ataman R, Serdengecti K. Colchicine neuromyopathy: a report of six cases. Clin Exp Rheumatol.
Ding J, Shang X, Zhang Z, et al. FDA-approved medications that impair human spermatogenesis. Oncotarget. 2017;8(6):10714-10725. doi:10.18632/oncotarget.12956
Indraratna PL, Virk S, Gurram D, Day RO. Use of colchicine in pregnancy: a systematic review and meta-analysis. Rheumatology (Oxford). 2018;57(2):382-387. doi:10.1093/rheumatology/kex353

Additional Reading

Colchicine. RxList. The Internet Drug Index.
Kelley's Textbook of Rheumatology. Elsevier. Ninth edition. Chapter 95: Clinical Features and Treatment of Gout - Colchicine.
Colcrys.
Colchicine. MedlinePlus.